Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj

Kangstem Biotech

Status: Unknown

Conditions: Rheumatoid Arthritis

Treatments: Drug: FURESTEM-RA Inj.

Study type: Observational

Funder types: Industry

Identifiers

NCT03106259

KSTBT_FURESTEM_RA_EXT

Details and patient eligibility

About

Observational Study to evaluate the safety of FURESTEM-RA lnj. in moderate to severe rheumatoid arthritis patients who participated in phase 1 clinical trial of FURESTEM-RA lnj.

Full description

This is a observational study, single center, open label, study of safety of FURESTEM-RA Inj. in subjects with moderate to severe rheumatoid arthritis.

Subjects participating in this observational study originally participated in study FURESTEM-RA Inj.

[NCT02221258]

Enrollment: 9 patients

Sex: All

Ages: 19 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects participating in this observational study originally participated in study FURESTEM-RA Inj.[NCT02221258]
• Subject who understands and voluntarily sign an informed consent form

Exclusion criteria

• In case follow-up is not possible from end of clinical trial Phase 1 to end of this study period

Trial design

9 participants in 1 patient group

Non-Interventional Study

Description:

Subjects participating in this observational study originally participated in study FURESTEM-RA Inj.\[NCT02221258\]

Treatment:

Drug: FURESTEM-RA Inj.